Literature DB >> 8735227

Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study.

S J Augood1, R L Faull, D R Love, P C Emson.   

Abstract

The expression of enkephalin and substance P messenger RNAs was examined in the caudate-putamen of human post mortem tissue from control and Huntington's disease tissue using in situ hybridization techniques and human specific enkephalin and substance P [35S] oligonucleotides. Macroscopic and microscopic quantification of enkephalin and substance P gene expression was carried out using computer-assisted image analysis. Tissue was collected from six control cases with no sign of neurological disease and six Huntington's disease cases ranging from grades 0 to 3 as determined by neuropathological evaluation. The clinical and pathological diagnosis of Huntington's disease was confirmed unequivocally by genetic analysis of the CAG repeat length in both copies of IT15, the Huntington's disease gene. A marked reduction in both enkephalin and substance P messenger RNAs was detected in all regions of the caudate nucleus and putamen in Huntington's disease grades 2/3 when compared to controls; in the dorsal caudate few enkephalin or substance P messenger RNA-positive cells were detected. For the early grade (0/1) Huntington's disease cases, a heterogeneous reduction in both enkephalin and substance P messenger RNAs were noted; for enkephalin messenger RNA the striatal autoradiograms displayed a conspicuous patchy appearance. Detailed cellular analysis of the dorsal caudate revealed a striking reduction in the number of enkephalin and substance P messenger RNA-positive cells detected and in the intensity of hybridization signal/cell. These data suggest that both the "indirect" GABA/enkephalin and "direct" GABA/substance P pathways are perturbed very early in the course of the disease and that these early changes in chemical signalling may possibly underlie the onset of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735227     DOI: 10.1016/0306-4522(95)00595-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  29 in total

1.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Authors:  Birgit Zucker; Jibrin A Kama; Alexandre Kuhn; Doris Thu; Lianna R Orlando; Anthone W Dunah; Ozgun Gokce; David M Taylor; Johann Lambeck; Bernd Friedrich; Katrin S Lindenberg; Richard L M Faull; Cornelius Weiller; Anne B Young; Ruth Luthi-Carter
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

4.  Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress.

Authors:  Hyungwoo Nam; Ramesh Chandra; T Chase Francis; Caroline Dias; Joseph F Cheer; Mary Kay Lobo
Journal:  Neuropsychopharmacology       Date:  2019-05-27       Impact factor: 7.853

5.  Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.

Authors:  Zhihong Guo; Gay Rudow; Olga Pletnikova; Kari-Elise Codispoti; Brent A Orr; Barbara J Crain; Wenzhen Duan; Russell L Margolis; Adam Rosenblatt; Christopher A Ross; Juan C Troncoso
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

Review 6.  Huntington's Disease.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 7.  Drug targeting of dysregulated transcription in Huntington's disease.

Authors:  Aleksey G Kazantsev; Steven M Hersch
Journal:  Prog Neurobiol       Date:  2007-02-23       Impact factor: 11.685

8.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

Review 9.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

Review 10.  The expanding role for chromatin and transcription in polyglutamine disease.

Authors:  Ryan D Mohan; Susan M Abmayr; Jerry L Workman
Journal:  Curr Opin Genet Dev       Date:  2014-08-11       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.